TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7127989
Drug: Teaspoon for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teaspoon for medication delivery
Study: 20215488
Drug: Once-weekly gym-based
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-weekly gym-based exercise programme
Study: 20215488
Drug: Twice-weekly gym-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly gym-based exercise programme
Study: 15250255
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (3 g/d)
Study: 11236069
Drug: Pindolol 5
Normalized name: pindolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 5 mg three times a day
Study: 9315414
Drug: 30 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms ethinyl estradiol and 2.00 mg dienogest
Study: 29099421
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg daily with propranolol
Study: 26259978
Drug: Conventional pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pen injection of insulin aspart
Study: 24050578
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules three times a day for two months
Study: 21878082
Drug: fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: fixed combination amlodipine/valsartan
Study: 15467597
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg b.i.d.)
Study: 19407662
Drug: Pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (40 mg b.i.d.)
Study: 9210707
Drug: Combined immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined immunotherapy with IL-2 and LAK cells after chemotherapy or radiotherapy (Group A)
Study: 9210707
Drug: Control standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control standard therapy (Group B)
Study: 9210707
Drug: Combined immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined immunotherapy (Group A)
Study: 2655683
Drug: Homoeopathic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homoeopathic preparation
Study: 21415581
Drug: Dobutamine stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine stress echocardiography (DSE) at peak infusion (40 μg/kg/min)
Study: 18721181
Drug: Proactive airway
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive airway clearance (AC) strategy, performed twice daily
Study: 16669959
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (aminosalicylates and weekly tapered corticosteroids)
Study: 16669959
Drug: Heparin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin therapy (standard therapy plus enoxaparin 100 Anti‐Xa IU/kg/day subcutaneously)
Study: 11728290
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (16 mg once daily, titrated to 32 mg as needed, with hydrochlorothiazide 12.5 mg as needed)
Study: 8126257
Drug: Misoprostol 800
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 800 mcg/day
Study: 3110681
Drug: L-carnitine added
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine added to dialysis fluid at a final concentration of 100 mumol/l
Study: 20587129
Drug: Real rTMS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real rTMS treatment (n=14)
Study: 20587129
Drug: Sham rTMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rTMS treatment (n=14)
Study: 18156403
Drug: Lycopene at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene at a dose of 15 mg/d for 6 months
Study: 3426370
Drug: Loperamide (Imodium)
Normalized name: loperamide Oral Capsule [Imodium]
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loperamide (Imodium) at an average dose of 20 to 25 drops/kg/24 h (0.16 to 0.20 mg/kg/24 h), given every 8 hours for at least 48 hours.
Study: 29998815
Drug: Pre-operative analgesics
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative analgesics (paracetamol and ibuprofen)
Study: 22542118
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for mild gestational diabetes mellitus
Study: 20565484
Drug: Airsonett Airshower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Airsonett Airshower (AA) treatment with allergen-free air during night sleep
Study: 12641688
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg.kg(‐1))
Study: 12641688
Drug: Tramadol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (2 mg.kg(‐1))
Study: 2005049
Drug: Minimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal treatment (control group)
Study: 6193666
Drug: Admixture group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admixture group: 20 ml dextran 1, 15% (Promiten) mixed with 500 ml dextran 70 (Macrodex) or dextran 40 (Rheomacrodex)
Study: 6193666
Drug: Preinjection group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preinjection group: 20 ml dextran 1, 15% administered before the infusion of dextran 70 or 40
Study: 27553442
Drug: PCFNB (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCFNB (bolus infusion of 3 ml with a lockout time of 30 min and no basal infusion)
Study: 27553442
Drug: cFNB (basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: cFNB (basal infusion of 6 ml/h using a dummy bolus button)
Study: 24132707
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ondansetron film-coated tablets (test product)
Study: 22263710
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance treatment (MMT) initiated prior to release from incarceration
Study: 19021604
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative dose of ciprofloxacin (2 tablets of 500 mg each, 2 hours before biopsy)
Study: 2802123
Drug: Propofol 2.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.15 mg/kg
Study: 2802123
Drug: Thiopentone 4.53
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 4.53 mg/kg
Study: 345570
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron therapy for anaemic adult villagers
Study: 345570
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron and/or TCE for children aged 5-14 years
Study: 30707970
Drug: Genistein treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein treatment
Study: 26222559
Drug: ISIS 304801
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 304801 (100 mg)
Study: 26222559
Drug: ISIS 304801
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 304801 (200 mg)
Study: 26222559
Drug: ISIS 304801
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 304801 (300 mg)
Study: 26222559
Drug: ISIS 304801
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 304801 (200 mg, add-on to fibrates)
Study: 26222559
Drug: ISIS 304801
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 304801 (300 mg, add-on to fibrates)
Study: 26222559
Drug: ISIS 304801
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 304801 (all doses)
Study: 23821878
Drug: Simultaneous technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous technique (two injections at the same time)
Study: 23821878
Drug: Sequential technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential technique (one injection after the other)
Study: 21875546
Drug: BUD/FM pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/FM pMDI 160/4.5 μg × 2 inhalations (320/9 μg) twice daily
Study: 21875546
Drug: BUD pMDI
Normalized name: Clove buds
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD pMDI 160 μg × 2 inhalations (320 μg) twice daily
Study: 18001802
Drug: Toremifene 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 80 mg per day
Study: 11097536
Drug: Neostigmine (0.005,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.005, 0.01, 0.02, or 0.05 mg x kg(‐1))
Study: 11097536
Drug: Edrophonium (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium (0.1, 0.2, 0.4, or 1 mg x kg(‐1))
Study: 3718908
Drug: Topical haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical haloperidol
Study: 29792287
Drug: GLPG1690 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1690 (600 mg oral once daily for 12 weeks)
Study: 24519563
Drug: Aminophylline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (75 mg intravenous, administered 90 seconds after (99m)Tc‐tetrofosmin injection)
Study: 18927301
Drug: Immunohistochemistry test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemistry test using five monoclonal antibodies
Study: 10815320
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (FEC-G) in addition to amikacin-ceftriaxone and other antibiotics
Study: 10815320
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic therapy without granulocyte colony-stimulating factor
Study: 1472833
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg per day
Study: 1472833
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg per day
Study: 1472833
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg per day + Gemfibrozil 450 mg per day
Study: 6424087
Drug: Intravenous nitrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitrogen intake (290 to 579 mg/kg/d)
Study: 6424087
Drug: Nitrogen intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen intake (280 mg/kg/d)
Study: 6424087
Drug: Recommended intravenous
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended intravenous amino acid intakes (2.3 to 2.7 g/kg/d)
Study: 26850265
Drug: Subjects on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects on Tamoxifen or no endocrine therapy
Study: 26850265
Drug: Subjects on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects on aromatase inhibitors (AIs)
Study: 26850265
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with serum Vitamin D levels 20-29 ng/mL
Study: 18827210
Drug: 4-IM (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-IM (intramuscular administration of AVA at 0, 2, and 4 weeks and 6 months; n = 165-170)
Study: 18827210
Drug: 3-IM (reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-IM (reduced 3-dose schedule of AVA; n = 501)
Study: 18827210
Drug: 4-SQ (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-SQ (subcutaneous administration of AVA at 0, 2, and 4 weeks and 6 months; n = 165-170)
Study: 18827210
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline injections at the same time intervals; n = 169)
Study: 18827210
Drug: Route of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration
Study: 10464886
Drug: Budesonide Turbuhaler
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide Turbuhaler 400 micrograms once daily in the evening
Study: 10464886
Drug: Budesonide Turbuhaler
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide Turbuhaler 200 micrograms twice daily
Study: 10464886
Drug: Budesonide Turbuhaler
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide Turbuhaler 200 micrograms once daily during the first open treatment period
Study: 10464886
Drug: Budesonide Turbuhaler
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide Turbuhaler 100 micrograms once daily during the second open treatment period
Study: 2169371
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (60 mg daily)
Study: 27770279
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + Temozolomide (TMZ) 75-100 mg/m2 day 1-21 of 28 day cycle
Study: 27770279
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + Irinotecan (CPT) 125 mg/m2 every 2 weeks
Study: 9670867
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone and exercise intervention
Study: 31174846
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg scopolamine
Study: 3126956
Drug: beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta blockers (prior treatment)
Study: 31256036
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral insulin (7.5 mg for 2 months, 22.5 mg for 2 months, 67.5 mg until age 36.0 months)
Study: 31256036
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral insulin
Study: 28291622
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ezetimibe 10mg/d and rosuvastatin 10mg/d)
Study: 28291622
Drug: High-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rosuvastatin (rosuvastatin 20mg/d)
Study: 23267856
Drug: GSK249320 (0.04,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK249320 (0.04, 0.4, 1.2, 3.5, 10, and 25 mg/kg)
Study: 19930866
Drug: Ramipril (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (up to 10 mg/day)
Study: 19930866
Drug: Losartan (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (up to 100 mg/day)
Study: 15021285
Drug: Intraoperative blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative blood loss in the hematoma group (762 ± 735 mL; median 500 mL)
Study: 15021285
Drug: Intraoperative blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative blood loss in the control group (415 ± 403 mL; median 300 mL)
Study: 11227030
Drug: 0.9 g
Normalized name: Mannose 0.9 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g n-3 PUFA as fish oil
Study: 11227030
Drug: 0.6 g
Normalized name: Ceo-Two, 0.9 g-0.6 g rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g n-3 PUFA as fish oil
Study: 11227030
Drug: 0.3 g
Normalized name: sorbitol 0.3 GM Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g n-3 PUFA as fish oil
Study: 3148139
Drug: Concurrent articulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent articulation
Study: 31862185
Drug: Neoadjuvant androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant androgen deprivation therapy (ADT)
Study: 25500337
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg algal DHA supplementation (3 capsules per day)
Study: 25500337
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg algal DHA supplementation
Study: 23069814
Drug: Mechlorethamine, 0.02%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechlorethamine, 0.02%, gel
Study: 23069814
Drug: Mechlorethamine, 0.02%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechlorethamine, 0.02%, compounded ointment
Study: 18218285
Drug: Fast-dissolving ibuprofen
Normalized name: melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fast-dissolving ibuprofen caplets
Study: 18218285
Drug: Regular release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular release ibuprofen caplets
Study: 11974477
Drug: Surgical intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical intervention (not specified dosage or duration)
Study: 8077573
Drug: 90 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mmol/L L‐glutamine added to standard WHO oral rehydration salts (WHO‐ORS)
Study: 8077573
Drug: Standard WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard WHO oral rehydration salts (WHO‐ORS)
Study: 2572120
Drug: Corticosteroid cream
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid cream (clobetasol propionate)
Study: 2572120
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (base of the steroid cream)
Study: 796950
Drug: Ketoprofen (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (administered rectally at a dosage of 200 mg daily)
Study: 26650153
Drug: Endobronchial valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial valve treatment (EBV group)
Study: 21890003
Drug: Added external
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Added external dead space (DS) 200 mL
Study: 21890003
Drug: Added external
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Added external dead space (DS) 400 mL
Study: 11675905
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg tablet daily for 5 days)
Study: 15013037
Drug: Co-amoxiclav (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (625 mg tablet every 8 hours for 7 days)
Study: 9237640
Drug: Lovastatin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (60 mg/day)
Study: 8217032
Drug: lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin 20 mg every day
Study: 31965873
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention (home pharmacist visit, illustrated medication instructions, follow-up phone call)
Study: 25434315
Drug: Lamivudine and
Normalized name: lamivudine and abacavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine and Adefovir dipivoxil (CLA) combination
Study: 25434315
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with HBV DNA levels detectable but <10(4) copies/mL
Study: 25434315
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with HBV DNA levels >10(4) copies/mL
Study: 22474997
Drug: Yougui Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yougui Capsules at 1.68 g tid for 12 weeks
Study: 10606840
Drug: Midazolam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.15 mg kg‐1)
Study: 10606840
Drug: Alpha-hydroxy-midazolam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-hydroxy-midazolam (0.15 mg kg‐1)
Study: 9148226
Drug: Torasemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide (20 mg/die)
Study: 9148226
Drug: Furosemide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (50 mg/die)
Study: 2946224
Drug: Etodolac 300
Normalized name: etodolac 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 300 mg bid
Study: 2946224
Drug: Etodolac 500
Normalized name: etodolac 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 500 mg bid
Study: 2946224
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg qd
Study: 18029292
Drug: Optimised pharmacotherapy
Normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised pharmacotherapy for CHF
Study: 12009084
Drug: Leukocyte depletion
Normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte depletion by filtration with full-dose aprotinin
Study: 28495642
Drug: Lenalidomide therapy
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide therapy (initiated at 5 mg every other day, increased to 10 mg daily if tolerated)
Study: 28495642
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (withdrawal of immunosuppression followed by donor lymphocyte infusion)
Study: 25577762
Drug: Selective prediction-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective prediction-based treatment
Study: 23643110
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to treatment pathways
Study: 19415804
Drug: MAL 160
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL 160 mg/g with 1 h incubation
Study: 19415804
Drug: MAL 160
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL 160 mg/g with 3 h incubation
Study: 19415804
Drug: MAL 80
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL 80 mg/g
Study: 9506002
Drug: Venlafaxine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (50 mg every 8 hours for 7 days)
Study: 9506002
Drug: Ethanol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.5 g/kg on days 5 and 7)